Opinion

Video

The Potential Role of TKIs in HER2-Mutated NSCLC

Author(s):

Edgardo S. Santos, MD, FACP, FCCP,Martin Dietrich, MD, PhD

Edward Kim, MD, MBA, describes the potential role of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2-mutated non–small cell lung cancer.

Related Videos
Alexis LeVee, MD
4 experts are featured in this series.
Related Content
ES-SCLC | catalin – stock.adobe.com
January 6th 2025

Tarlatamab Earns UK Approval for Previously Treated ES-SCLC

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, the Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Susan M. O'Brien, MD, associate director, Clinical Science, Chao Family Comprehensive Cancer Center, medical director, Sue & Ralph Stern Center for Clinical Trials & Research, professor, medicine, Division of Hematology/Oncology, University of California Irvine School of Medicine
December 31st 2024

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 3rd 2025

Taletrectinib Approved in China for Locally Advanced/Metastatic ROS1+ NSCLC

Alex F. Herrera, MD, chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, associate medical director, Briskin Center for Clinical Research, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
December 13th 2024

Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD

Savolitinib Plus Osimertinib for Pretreated EGFR+ NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 2nd 2025

Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification

Lung Cancer | Image Credit: © catalina – stock.adobe.com
January 2nd 2025

European Commission Approves Lazertinib Plus Amivantamab in First-Line EGFR-Mutated NSCLC